BOJI MEDICAL TECHNOLOGY CO.,LTD. Boji Medical Technology Co.,Ltd. Stock
Equities
300404
CNE100001Y00
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.75 CNY | +1.35% |
|
-0.59% | -24.58% |
| Sales 2021 | 324M 44.74M | Sales 2022 | 424M 58.47M | Capitalization | 2.88B 398M |
|---|---|---|---|---|---|
| Net income 2021 | 38M 5.24M | Net income 2022 | 27M 3.73M | EV / Sales 2021 | 10 x |
| Net cash position 2021 | 373M 51.48M | Net cash position 2022 | 272M 37.51M | EV / Sales 2022 | 6.16 x |
| P/E ratio 2021 |
87.1
x | P/E ratio 2022 |
104
x | Employees | 1,186 |
| Yield 2021 |
0.14% | Yield 2022 |
0.13% | Free-Float | 58.86% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.35% | ||
| 1 week | -0.59% | ||
| Current month | -11.07% | ||
| 1 month | -16.15% | ||
| 3 months | -11.76% | ||
| 6 months | -21.33% | ||
| Current year | -24.58% |
1 week
6.32
6.83
1 month
6.278.08
Current year
5.039.17
1 year
5.0312.88
3 years
5.0312.88
5 years
5.0314.43
10 years
3.5942.43
| Managers | Title | Age | Since |
|---|---|---|---|
Ting Cun Wang
CEO | Chief Executive Officer | 59 | 11-06-10 |
Xiu Qing Ou
DFI | Director of Finance/CFO | 42 | 03-11-30 |
Bo Tan
BRD | Director/Board Member | 42 | 05-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ting Cun Wang
CEO | Chief Executive Officer | 59 | 11-06-10 |
Yu Ping Han
PRN | Corporate Officer/Principal | 51 | 08-10-31 |
Quan Zhu
BRD | Director/Board Member | 52 | 08-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 6.75 | +1.35% | 4,463,566 |
| 24-04-19 | 6.66 | -1.04% | 5,053,534 |
| 24-04-18 | 6.73 | -0.59% | 5,886,295 |
| 24-04-17 | 6.77 | +7.80% | 8,475,642 |
| 24-04-16 | 6.28 | -7.51% | 8,922,076 |
End-of-day quote Shenzhen S.E., April 21, 2024
More quotes
Boji Medical Technology Co Ltd is a China-based company that provides Contract Research Organization (CRO) services. The Company mainly provides one-stop CRO services for the development and production of new drugs and medical devices for domestic and foreign pharmaceutical companies and other research institutions. The Company's CRO services include pre-clinical research services, clinical research services, other consulting services, pharmaceutical Contract Development Manufacture Organization (CDMO) services, pre-clinical independent research and development services, and technology achievement transformation services. The Company mainly conducts its businesses in the domestic market.
Calendar
2024-04-24
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.58% | 356M | |
| -0.02% | 42.11B | |
| +48.71% | 40.08B | |
| +5.04% | 40B | |
| -11.32% | 26.87B | |
| +5.25% | 24.58B | |
| -23.83% | 18.44B | |
| -1.62% | 11.94B | |
| +22.75% | 11.66B | |
| +6.44% | 11.01B |
- Stock Market
- Equities
- 300404 Stock
